339 related articles for article (PubMed ID: 26660439)
1. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
2. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
3. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
4. The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
Borchmann P; Schnell R
Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797
[TBL] [Abstract][Full Text] [Related]
5. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
6. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
[TBL] [Abstract][Full Text] [Related]
7. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
9. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
10. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
11. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
[TBL] [Abstract][Full Text] [Related]
14. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
15. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
16. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
17. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
18. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.
Vann KR; Ergün Y; Zencir S; Oncuoglu S; Osheroff N; Topcu Z
Bioorg Med Chem Lett; 2016 Apr; 26(7):1809-12. PubMed ID: 26906637
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]